Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2025-06-22 15:24:18 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.ejca.2025.115397
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0959804925001789
其他信息:
出版社: Elsevier BV
作者: Philippe L. Bedard; Komal L. Jhaveri; Melissa K. Accordino; Prof Andrés Cervantes; Valentina Gambardella; Erika Hamilton; Prof Antoine Italiano; Prof Kevin Kalinsky; Prof Ian E. Krop; Mafalda Oliveira; Prof Peter Schmid; Cristina Saura; Prof Nicholas Turner; Andrea Varga; Sravanthi Cheeti; Anwesha Dey; Stephanie Hilz; Katherine E. Hutchinson; Yanling Jin; Stephanie Royer-Joo; Ubong Peters; Noopur Shankar; Jennifer L. Schutzman; Junko Aimi; Kyung Song; Dejan Juric